Breakthroughs that break through pain and addiction

Chromocell is developing innovative non-addictive, drugs to treat
chronic neuropathic and acute and chronic eye pain.

An urgent
need

Idiopathic Small Fiber Neuropathy (iSFN) and Erythromelalgia (EM) our first two indication, both eligible for orphan drug designation, providing both substantial market potential and faster approval. There are currently no approved drugs for either indication.

Fast-track IND STATUS to other indications

Our lead compound is now in phase 2a studies after the FDA reviewed and approved our Phase 1 results and approach. A breakthrough designation by the FDA would enable a 2026 NDA.

A NON-OPIOID ALTERNATIVE

Our patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post surgical, and chemotherapy induced.

“WE BELIEVE OUR LEAD COMPOUND WILL PROVIDE THE FOUNDATION FOR SIGNIFICANT ADVANCES IN NON-OPIOID TREATMENT OF ERYTHROMELALGIA, IDIOPATHIC SMALL FIBER NEURPATHY, EYE PAIN AND OTHER INDICATIONS.”
Frank Knuettel II • CEO & Chief Financial Officer